VVEO3 logo

CM Hospitalar S/A Stock Price

BOVESPA:VVEO3 Community·R$426.3m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 14 Fair Values set on narratives written by author

VVEO3 Share Price Performance

R$1.35
0.01 (0.75%)
R$2.00
Fair Value
R$1.35
0.01 (0.75%)
32.5% undervalued intrinsic discount
R$2.00
Fair Value
Price R$1.35
AnalystHighTarget R$2.00
AnalystConsensusTarget R$1.51
AnalystLowTarget R$1.00

VVEO3 Community Narratives

AnalystHighTarget·
Fair Value R$2 32.5% undervalued intrinsic discount

Portfolio Pruning And Margin Expansion Will Drive A Powerful Healthcare Turnaround

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value R$1.51 10.4% undervalued intrinsic discount

Operational Turnaround And Aging Population Trends Will Support Long-Term Healthcare Demand

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AnalystLowTarget·
Fair Value R$1 35.0% overvalued intrinsic discount

Execution Risks From Integration And Contract Repricing Will Pressure Margins Over Coming Years

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
R$2
32.5% undervalued intrinsic discount
Profit Margin
0.32%
Future PE
30.42x
Price in 2028
R$4.16
R$1
35.0% overvalued intrinsic discount
Profit Margin
0.076%
Future PE
0.52x
Price in 2028
R$0.02

Trending Discussion

Updated Narratives

VVEO3 logo

Operational Turnaround And Aging Population Trends Will Support Long-Term Healthcare Demand

Fair Value: R$1.51 10.4% undervalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
VVEO3 logo

Portfolio Pruning And Margin Expansion Will Drive A Powerful Healthcare Turnaround

Fair Value: R$2 32.5% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
VVEO3 logo

Execution Risks From Integration And Contract Repricing Will Pressure Margins Over Coming Years

Fair Value: R$1 35.0% overvalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Slight risk with moderate growth potential.

4 Risks
3 Rewards

CM Hospitalar S/A Key Details

R$11.6b

Revenue

R$9.9b

Cost of Revenue

R$1.7b

Gross Profit

R$1.7b

Other Expenses

R$18.2m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
May 12, 2026
0.058
14.43%
0.16%
177.6%
View Full Analysis

About VVEO3

Founded
2010
Employees
6000
CEO
André Juliano
WebsiteView website
ri.viveo.com.br

CM Hospitalar S/A engages in the distribution of hospital materials, medicines, and nutrition products in Brazil. The company offers ophthalmic agent, adrenergic and thrombopoietin agonist, aminoglycosides, painkiller, anesthetics, receptor antagonist, anti-hemorrhoidal, antihypertensives, systemic antihistamine, and orthopedic therapy materials; and anti-inflammatories, anti-TNF, antacid, antiandrogen, antianemic, anti-asthmatic, antibiotic, anticoagulant, anticonvulsant, monoclonal antibody, antineoplastics, antiparathyroid drugs, antiparkinsonian, antipsychotic, systemic antipsoriasis, antirheumatics, anti-varicose, anti-growth, antidepressant, antidiabetic, antidiuretic, antidote, antiemetics and antinauseants, anti-migraine, antiepileptics, antiestrogens, antifibrinolytic, antiflatulent, antifungal, antihemorrhagic, antimicrobial, and antiviral medicines. It also provides beta blocker, carbohydrate, cycloplegic, contraceptive, contrast, special control, corticosteroid, topical debrider, diuretic, electrolyte, pancreatic enzyme, erythropoietin, uterine and cardiac stimulant, growth factor, granulocyte colony stimulating factor, gastroprokinetic, systemic hemostatic, heparins, hepatoprotector and lipotropic, hormone, adeno-pituitary and growth hormone, immunoglobulin, immunosuppressant, labor inducer, proton pump and phosphodiesterase inhibitor, bone resorption inhibitor, platelet aggregation inhibitor, adenosine diphosphate receptor antagonist, proton pump and interleukin inhibitor, proprotein convertase subtilisin/kexin type 9 inhibitor, and calcium reabsorption inhibitor medicines. In addition, the company distributes orthopedic products, compression socks, and diapers; and transports medical and hospital cargo. Further, it provides support infrastructure and assistance, as well as pharmaceutical monitoring to patients at home; and offers wipes and wet towels. CM Hospitalar S/A was incorporated in 2010 and is headquartered in Ribeirão Preto, Brazil.

Recent VVEO3 News & Updates

Recent updates

No updates